A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers.
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2016
At a glance
- Drugs Pilaralisib (Primary) ; Seribantumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 28 Dec 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 12 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov record.